Foundayo Is Lilly’s New GLP-1 Pill — Here’s What Nobody’s Telling Women Over 40

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published April 8, 2026 • Updated April 8, 2026

On April 1, 2026, the FDA approved Foundayo — Eli Lilly’s new once-daily GLP-1 pill for weight loss. Within 48 hours, every health outlet in the country ran the same headline: a convenient pill, no needles, no fasting rules, starting at $149 a month. The internet declared it a breakthrough.

Let me be clear: Foundayo is a reasonable drug. It works. It’s a legitimate option for certain patients. But the coverage I’m seeing is leaving out everything that matters to you if you’re a woman over 40 — especially if you’re in perimenopause or menopause.

Nobody is telling you that the trial data doesn’t separate results by hormonal status. Nobody is telling you that this pill produces almost half the weight loss of the injectable you’re comparing it to. Nobody is mentioning the birth control interaction. And nobody is telling you that Lilly designed this drug as a cheaper, less powerful maintenance tool — not front-line treatment. Here’s what I see in my practice: another GLP-1 that will be funneled to millions of women through apps with zero hormonal evaluation, and when it underperforms, those women will blame themselves.

What Foundayo Actually Is — And What It Isn’t

First, let’s cut through the confusion, because I’m already seeing patients who think Foundayo is “Zepbound in pill form.” It is not.

Foundayo’s active ingredient is orforglipron, a completely different molecule from tirzepatide (the drug in Zepbound and Mounjaro). Here’s the critical distinction:

• Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist — it activates two gut hormone pathways simultaneously. Weekly injection. Currently the most effective weight loss drug on the market.
• Foundayo (orforglipron) is a GLP-1-only receptor agonist — one pathway. Daily pill. It’s a small-molecule compound, not a peptide, which is why it survives stomach acid and can be taken orally without fasting.

That “small molecule” part is what makes Foundayo genuinely different from oral Wegovy (semaglutide), approved in December 2025, which requires an empty stomach, only plain water, and a 30-minute wait before eating. Foundayo has none of those restrictions — any time of day, with food, with coffee. That is a real convenience advantage. But convenience and efficacy are two different things.

The Weight Loss Numbers Nobody Is Contextualizing for Women

The data shows that Foundayo works. What the data also shows is that it works significantly less well than the injectables you’re comparing it to.

In the Phase 3 ATTAIN-1 trial, published in The New England Journal of Medicine in 2025, adults with obesity taking the highest dose of orforglipron lost an average of 12.4% of body weight (about 27.3 pounds) over 72 weeks. About 35.9% of participants on that dose achieved 15% or more weight loss.

Now compare that to the head-to-head data we already have:

• Zepbound (tirzepatide): 20.2% weight loss in the head-to-head SURMOUNT-5 trial (The New England Journal of Medicine, 2025), vs. 13.7% for semaglutide at 72 weeks. In SURMOUNT-1, tirzepatide hit 20.9% at the highest dose.
• Oral Wegovy (semaglutide pill): Approximately 16.6% weight loss in the OASIS 4 trial at 64 weeks — also more than Foundayo.
• Foundayo (orforglipron): 12.4% at highest dose, 72 weeks.

Foundayo produces roughly 40% less weight loss than Zepbound. For a woman who needs to lose 60 pounds, the difference between 12% and 21% is the difference between losing 26 pounds and losing 46 pounds.

And here’s the part that keeps me up at night. These trials did not stratify results by menopausal status. We already know from the January 2026 Mayo Clinic study in The Lancet Obstetrics, Gynaecology, & Women’s Health that postmenopausal women combining hormone replacement therapy with tirzepatide lost 35% more weight than women on tirzepatide alone. If hormones make that much difference with the stronger drug, imagine what happens when you give a hormonally depleted woman the weaker one with no evaluation at all.

The 12.4% number is a population average. Your number, if nobody has checked your estradiol, your progesterone, your hormonal status — could be far lower.

The Birth Control Interaction That Should Be Front-Page News

This is buried in the prescribing information, and I have yet to see a single consumer-facing article lead with it.

The FDA label for Foundayo states that it may reduce the effectiveness of oral hormonal contraceptives. The mechanism: orforglipron slows gastric emptying (that’s part of how it suppresses appetite), which can interfere with absorption of the birth control pill before it reaches the bloodstream. The clinical interaction study hasn’t been completed, so the label takes a cautionary approach — use backup or non-oral contraception for 30 days after starting Foundayo, and again for 30 days after every dose increase.

Let me tell you who this affects most: women in their late 30s and 40s. Women in perimenopause whose cycles are irregular. Women who think they can’t get pregnant because they haven’t had a period in three months — but they can.

Foundayo has six dose levels, and patients titrate up gradually. That means a woman could need backup contraception for the better part of her first four to five months on the drug. Is anyone at the telehealth company that prescribed it in 90 seconds going to walk her through that?

If you’re a woman of reproductive age considering Foundayo, talk to your physician — not an app — about non-oral contraceptive options like IUDs, implants, or injectable contraception that won’t be affected by delayed gastric emptying.

Lilly’s Maintenance Strategy — And Why It Should Concern You

Here’s something the press releases are framing as good news that I want you to read more carefully.

Lilly didn’t design Foundayo to compete with Zepbound. They designed it to follow Zepbound. The company’s own CEO, David Ricks, has said that Foundayo is positioned as a “foundational” GLP-1 — the drug you step down to after you’ve done the heavy lifting with an injectable. Lose weight on the shot, maintain on the pill.

The ATTAIN-MAINTAIN trial tested exactly this. Participants who completed 72 weeks on Zepbound or Wegovy in SURMOUNT-5 were switched to daily orforglipron for 52 weeks. Those switching from Wegovy maintained their weight almost completely (average regain of 0.9 kg). But participants switching from Zepbound regained an average of 5 kg (about 11 pounds) over the year.

Compare that to placebo: people who switched from injectables to nothing regained about 9 kg. So Foundayo is better than nothing — but “better than nothing” is a low bar for a drug costing $149–$349 a month.

Here’s what concerns me about this playbook: at no point in the ATTAIN-MAINTAIN protocol was there a hormonal evaluation at the transition point. Nobody checked whether the woman switching from Zepbound to Foundayo had declining estrogen driving insulin resistance. Nobody assessed whether she needed hormonal optimization to maintain her results on a less potent drug. The assumption was that one pill fits all.

For women in midlife, that assumption is wrong. And it will cost you 11 pounds — or more.

Why a Pill From a Telehealth App Still Isn’t Medicine

Foundayo makes the prescription-mill problem worse, not better. With injectables, at least there was a small barrier: patients had to learn to self-inject, pharmacies had cold-chain requirements, and cost was high enough that some oversight was baked in. A daily pill at $149 with free home delivery via LillyDirect removes every friction point. Great for access. Terrible for care quality.

What I see happening — and what is already happening as of this week — is this:

• No comprehensive lab work. No 50+ biomarker panel. No metabolic assessment. No hormonal evaluation. Most of these platforms never order labs.
• No ongoing physician oversight. A 5-minute video call with a PA, once, is not care. Nobody is monitoring body composition, bone density, or hormones over time.
• No exit strategy. What happens when you want to stop? When Foundayo doesn’t work? When you plateau at month three? The script mill doesn’t have answers because it doesn’t know your biology.
• No bone or muscle protection. Research at the 2026 AAOS Annual Meeting showed GLP-1 users face approximately 30% higher osteoporosis risk. Up to 40% of GLP-1 weight loss may come from lean mass. For women in menopause already losing bone and muscle, nobody at a prescription app is ordering your DEXA scan.

A pill that’s easier to prescribe is not automatically safer. In some ways, it’s more dangerous — because it lowers the perceived bar for what counts as “treatment.”

What a Real Foundayo Protocol Looks Like — With Physician Oversight

Foundayo can be a useful tool. But a tool without a protocol is just a product you’re paying for monthly. Here’s how I approach it at Gaya Wellness.

Step 1: Assess your biology first.
Every woman gets a comprehensive 50+ biomarker panel before I prescribe anything. Full hormonal panel — estradiol, progesterone, total and free testosterone, DHEA-S. Full metabolic panel — fasting insulin, cortisol, thyroid, lipids. You cannot choose the right medication without this data.

Step 2: Address the hormonal foundation.
If you’re in perimenopause or menopause and a candidate for HRT, that conversation happens first. The Mayo Clinic data says this decision alone is worth 35% more weight loss. You do not skip this step to save time.

Step 3: Choose the right GLP-1 for your situation.
For some women, that’s injectable tirzepatide or semaglutide for aggressive initial loss. For others — those at target weight who need maintenance, or who genuinely cannot tolerate injections — Foundayo could be a legitimate option. The point is that someone who knows your biology makes the call.

Step 4: Monitor, adjust, protect.
Weekly check-ins. Body composition tracking. DEXA scans for bone density. Protein targets and resistance training to preserve lean mass. Dose adjustments based on your actual metabolic response — not a generic titration schedule.

The Weight Loss Concierge program exists because this level of care does not exist at a company that approved your Foundayo prescription based on a questionnaire.

• Foundation (GLP-1 Access) — $149/mo: Physician-led support with prior authorization assistance for brand-name medications like Wegovy, Zepbound, or Foundayo. You bring the medication; we bring the protocol.
• Premium (GLP-1 Included) — $349/mo: Everything in Foundation plus compounded semaglutide or tirzepatide shipped to your door. Physician-managed dosing. Custom meal plans.
• Concierge (GLP-1 + HRT) — $549/mo: The complete protocol. GLP-1 medication combined with bioidentical hormone replacement therapy. This is the tier the Mayo Clinic data points to — and the one that produces the best outcomes for women in midlife.

You Haven’t Failed — But Lilly’s Marketing Isn’t Telling You the Whole Story

Let me say something directly to the woman reading this who just saw a Foundayo ad, or whose friend told her about a $149 pill that “finally makes GLP-1s accessible.”

The problem with Foundayo is not that it exists. It’s a real drug that works for some patients. The problem is who it will be prescribed to, how, and with how little evaluation.

It will be prescribed to millions of women over 40 — the demographic with the highest rates of obesity in the country — through apps that never check their hormones. When those women lose 7% instead of 12%, or plateau at month three, or regain weight after switching from an injectable, they’ll think the problem is them. It isn’t.

Your body changed. Your metabolism rewrote its rules. And a pill without a protocol is not a treatment plan.

If you’re considering Foundayo — or any GLP-1 — and you’re a woman in midlife, the question isn’t “which pill?” It’s: has anyone looked at the whole picture? Your hormones. Your metabolic markers. Your bone density. Your actual biology. If the answer is no, that’s where we come in.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.